Status:
RECRUITING
Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
Lead Sponsor:
Kafrelsheikh University
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Along with the current clinical trial, the efficacy and safety of ticagrelor and aspirin administered within the first 24 hours of first-ever ischemic stroke compared to cilostazol and aspirin were as...
Detailed Description
The investigators will conduct a randomized controlled trial between December 2021 and February 2024 after approval of the ethics committee of the faculty of medicine at Kafr el-Sheik University. The...
Eligibility Criteria
Inclusion
- the investigators included both genders with eligible ages ranging between 18-75 years, with the first-ever presentation with acute minor ischemic stroke or TIA who received antiplatelet treatment within the first 24 hours of the onset of ischemic stroke. Patients are not eligible for rt-PA treatment
Exclusion
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT06196047
Start Date
December 1 2023
End Date
December 30 2024
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt, 33155